A low level of baseline ADORA3 mRNA expression in blood is associated with nonresponse to methotrexate and could serve as a potential biomarker for distinguishing response to methotrexate therapy in RA (33). The gene discussed is ADORA3; the disease is rheumatoid arthritis.